• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer.雄激素受体和 ERK 信号在雌激素受体阴性乳腺癌中的反馈回路。
Neoplasia. 2011 Feb;13(2):154-66. doi: 10.1593/neo.101324.
2
Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer.催乳素诱导蛋白介导雌激素受体阴性乳腺癌中的细胞侵袭并调节整合素信号传导。
Breast Cancer Res. 2012 Jul 20;14(4):R111. doi: 10.1186/bcr3232.
3
Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer.雄激素受体抑制剂与 MEK 的协同作用对雌激素受体阴性乳腺癌具有治疗意义。
Breast Cancer Res. 2011 Apr 1;13(2):R36. doi: 10.1186/bcr2858.
4
A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer.雌激素受体阴性乳腺癌中雄激素受体与ErbB2信号通路之间具有功能意义的相互作用。
Neoplasia. 2008 Jun;10(6):542-8. doi: 10.1593/neo.08274.
5
Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer.FOXA1 和 ErbB2 信号在雌激素受体阴性乳腺癌中的相互调控。
Neoplasia. 2012 Apr;14(4):283-96. doi: 10.1593/neo.12294.
6
Mediator of ERBB2-driven cell motility (MEMO) promotes extranuclear estrogen receptor signaling involving the growth factor receptors IGF1R and ERBB2.ERBB2 驱动的细胞迁移介质(MEMO)促进涉及生长因子受体 IGF1R 和 ERBB2 的核外雌激素受体信号传导。
J Biol Chem. 2013 Aug 23;288(34):24590-9. doi: 10.1074/jbc.M113.467837. Epub 2013 Jul 16.
7
Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer.在分子型大汗腺癌中,抑制雄激素受体和 Cdc25A 磷酸酶作为联合靶向治疗。
Cancer Lett. 2010 Dec 1;298(1):74-87. doi: 10.1016/j.canlet.2010.06.005. Epub 2010 Jul 6.
8
Targeting androgen receptor in estrogen receptor-negative breast cancer.针对雌激素受体阴性乳腺癌的雄激素受体。
Cancer Cell. 2011 Jul 12;20(1):119-31. doi: 10.1016/j.ccr.2011.05.026.
9
Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.三阴性乳腺癌中的大汗腺癌:大汗腺型浸润性导管癌为雌激素/孕激素受体阴性、雄激素受体阳性的新型定义。
Jpn J Clin Oncol. 2012 May;42(5):375-86. doi: 10.1093/jjco/hys034. Epub 2012 Mar 26.
10
A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells.Rac-Pak 信号通路对于 ErbB2 介导的人乳腺癌上皮细胞转化是必需的。
Oncogene. 2010 Oct 28;29(43):5839-49. doi: 10.1038/onc.2010.318. Epub 2010 Aug 16.

引用本文的文献

1
Do AR and TILs have any association with the efficacy of neoadjuvant treatment for HER2-positive breast cancer?AR和肿瘤浸润淋巴细胞(TILs)与HER2阳性乳腺癌新辅助治疗的疗效有何关联?
Medicine (Baltimore). 2025 Sep 5;104(36):e44364. doi: 10.1097/MD.0000000000044364.
2
Mechanistic Insights and Clinical Implications of ELK1 in Solid Tumors: A Narrative Review.ELK1在实体瘤中的机制见解与临床意义:一项叙述性综述
Cells. 2025 Aug 14;14(16):1257. doi: 10.3390/cells14161257.
3
Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities.非前列腺恶性肿瘤中的雄激素受体信号传导:挑战与机遇
Nat Rev Cancer. 2025 Feb;25(2):93-108. doi: 10.1038/s41568-024-00772-w. Epub 2024 Nov 25.
4
Androgen receptor expression and clinical characteristics in breast cancer.雄激素受体在乳腺癌中的表达与临床特征。
World J Surg Oncol. 2024 Sep 11;22(1):243. doi: 10.1186/s12957-024-03525-z.
5
Estrogen's sex-specific effects on ischemic cell death and estrogen receptor mRNA expression in rat cortical organotypic explants.雌激素对大鼠皮质器官型外植体缺血性细胞死亡及雌激素受体mRNA表达的性别特异性影响。
Aging Brain. 2024 Apr 16;5:100117. doi: 10.1016/j.nbas.2024.100117. eCollection 2024.
6
Treatments Targeting the Androgen Receptor and Its Splice Variants in Breast Cancer.针对乳腺癌中雄激素受体及其剪接变体的治疗方法。
Int J Mol Sci. 2024 Feb 2;25(3):1817. doi: 10.3390/ijms25031817.
7
Prognostic Role of Prolactin-Induced Protein (PIP) in Breast Cancer.催乳素诱导蛋白(PIP)在乳腺癌中的预后作用
Cells. 2023 Sep 11;12(18):2252. doi: 10.3390/cells12182252.
8
Beyond Prostate Cancer: An Androgen Receptor Splice Variant Expression in Multiple Malignancies, Non-Cancer Pathologies, and Development.超越前列腺癌:雄激素受体剪接变体在多种恶性肿瘤、非癌病理及发育过程中的表达
Biomedicines. 2023 Aug 7;11(8):2215. doi: 10.3390/biomedicines11082215.
9
Correlation between androgen receptor expression and pathological response rate in pre-operative HER2-positive breast cancer patients.术前 HER2 阳性乳腺癌患者雄激素受体表达与病理反应率的相关性。
J Cancer Res Clin Oncol. 2023 Sep;149(12):10109-10117. doi: 10.1007/s00432-023-04904-x. Epub 2023 Jun 2.
10
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far.管腔雄激素受体乳腺癌的潜在治疗靶点:我们目前所了解的情况。
Onco Targets Ther. 2023 Apr 7;16:235-247. doi: 10.2147/OTT.S379867. eCollection 2023.

本文引用的文献

1
Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations.分子大汗腺样分化是种系 PTEN 突变患者乳腺癌的一个常见特征。
Breast Cancer Res. 2010;12(4):R63. doi: 10.1186/bcr2626. Epub 2010 Aug 16.
2
Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer.在分子型大汗腺癌中,抑制雄激素受体和 Cdc25A 磷酸酶作为联合靶向治疗。
Cancer Lett. 2010 Dec 1;298(1):74-87. doi: 10.1016/j.canlet.2010.06.005. Epub 2010 Jul 6.
3
BEX2 has a functional interplay with c-Jun/JNK and p65/RelA in breast cancer.BEX2 在乳腺癌中与 c-Jun/JNK 和 p65/RelA 具有功能相互作用。
Mol Cancer. 2010 May 19;9:111. doi: 10.1186/1476-4598-9-111.
4
EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast.EGFR 和 HER-2/neu 在乳腺浸润性大汗腺癌中的表达。
Mod Pathol. 2010 May;23(5):644-53. doi: 10.1038/modpathol.2010.50. Epub 2010 Mar 5.
5
Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation.乳腺癌中的雄激素受体:在雌激素受体阳性肿瘤和具有大汗腺分化的雌激素受体阴性肿瘤中的表达。
Mod Pathol. 2010 Feb;23(2):205-12. doi: 10.1038/modpathol.2009.159. Epub 2009 Nov 6.
6
Expression of androgen receptors in primary breast cancer.雄激素受体在原发性乳腺癌中的表达。
Ann Oncol. 2010 Mar;21(3):488-492. doi: 10.1093/annonc/mdp510. Epub 2009 Nov 3.
7
Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family.基因表达荟萃分析支持存在具有雄激素受体作用的分子大汗腺癌,并提示其与表皮生长因子受体(ErbB)家族存在相互作用。
BMC Med Genomics. 2009 Sep 11;2:59. doi: 10.1186/1755-8794-2-59.
8
BEX2 regulates mitochondrial apoptosis and G1 cell cycle in breast cancer.BEX2 调控乳腺癌中线粒体凋亡和 G1 细胞周期。
Int J Cancer. 2010 Apr 1;126(7):1596-610. doi: 10.1002/ijc.24866.
9
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.MEK和磷脂酰肌醇3激酶抑制剂在基底样乳腺癌模型中的体内抗肿瘤活性。
Clin Cancer Res. 2009 Jul 15;15(14):4649-64. doi: 10.1158/1078-0432.CCR-09-0317. Epub 2009 Jun 30.
10
Soluble factors derived from stroma activated androgen receptor phosphorylation in human prostate LNCaP cells: roles of ERK/MAP kinase.来源于基质的可溶性因子激活人前列腺LNCaP细胞中的雄激素受体磷酸化:细胞外信号调节激酶/丝裂原活化蛋白激酶的作用
Prostate. 2009 Jun 15;69(9):949-55. doi: 10.1002/pros.20944.

雄激素受体和 ERK 信号在雌激素受体阴性乳腺癌中的反馈回路。

A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer.

机构信息

University of Queensland Diamantina Institute, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

出版信息

Neoplasia. 2011 Feb;13(2):154-66. doi: 10.1593/neo.101324.

DOI:10.1593/neo.101324
PMID:21403841
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3033594/
Abstract

Estrogen receptor (ER)-negative breast cancer is heterogeneous, and the biology of this disease has remained poorly understood. Molecular apocrine is a subtype of ER-negative breast cancer that is characterized by the overexpression of steroid-response genes such as AR and a high rate of ErbB2 amplification. In this study, we have identified a positive feedback loop between the AR and extracellular signal-regulated kinase (ERK) signaling pathways in molecular apocrine breast cancer. In this process, AR regulates ERK phosphorylation and kinase activity. In addition, AR inhibition results in the down-regulation of ERK target proteins phospho-RSK1, phospho-Elk-1, and c-Fos using an in vivo molecular apocrine model. Furthermore, we show that AR-mediated induction of ERK requires ErbB2, and AR activity, in turn, regulates ErbB2 expression as an AR target gene. These findings suggest that ErbB2 is an upstream connector between the AR and ERK signaling pathways. Another feature of this feedback loop is an ERK-mediated regulation of AR. In this respect, the inhibition of ERK phosphorylation reduces AR expression and CREB1-mediated transcriptional regulation of AR acts as a downstream connector between the AR and ERK signaling pathways in molecular apocrine cells. Finally, we demonstrate that AR-positive staining is associated with the overexpression of ERK signaling targets phospho-Elk-1 and c-Fos in ER-negative breast tumors, which further supports a cross-regulation between the AR and ERK signaling pathways in molecular apocrine subtype. This study demonstrates an AR-ERK feedback loop in ER-negative breast cancer with significant biologic and therapeutic implications in this disease.

摘要

雌激素受体(ER)阴性乳腺癌是异质性的,其生物学特性仍知之甚少。分子大汗腺癌是 ER 阴性乳腺癌的一种亚型,其特征是甾体反应基因如 AR 的过度表达和 ErbB2 扩增率高。在这项研究中,我们已经确定了分子大汗腺癌中 AR 和细胞外信号调节激酶(ERK)信号通路之间的正反馈环。在此过程中,AR 调节 ERK 的磷酸化和激酶活性。此外,使用体内分子大汗腺癌模型,AR 抑制导致 ERK 靶蛋白磷酸化 RSK1、磷酸化 Elk-1 和 c-Fos 的下调。此外,我们表明 AR 介导的 ERK 诱导需要 ErbB2,并且 AR 活性反过来又作为 AR 靶基因调节 ErbB2 表达。这些发现表明 ErbB2 是 AR 和 ERK 信号通路之间的上游连接器。该反馈环的另一个特征是 ERK 介导的 AR 调节。在这方面,抑制 ERK 磷酸化减少 AR 表达,并且 CREB1 介导的 AR 转录调节作为 AR 和 ERK 信号通路之间的下游连接器在分子大汗腺细胞中起作用。最后,我们证明 AR 阳性染色与 ER 阴性乳腺癌中 ERK 信号靶标磷酸化 Elk-1 和 c-Fos 的过度表达相关,这进一步支持了分子大汗腺亚型中 AR 和 ERK 信号通路之间的交叉调节。这项研究在 ER 阴性乳腺癌中证明了 AR-ERK 反馈环,这对该疾病具有重要的生物学和治疗意义。